Midbrain dopaminergic neuronal degeneration in a transgenic mouse model of familial amyotrophic lateral sclerosis

Familial amyotrophic lateral sclerosis has been linked in 15% of families to mutations in the gene encoding for copperzinc superoxide dismutase (Cu/Zn‐SOD), a key enzyme in the cellular defense mechanisms against free radical attack. We used a transgenic mouse model of familial amyotrophic lateral sclerosis (transgenic G1H mice) based on expression of mutant human Cu/Zn‐SOD to examine the influence of the transgene expression on midbrain dopaminergic neurons, cells that contain conspicuous amounts of this enzyme. At the time that 50% of motor neurons of the spinal cord were lost, we observed concurrent reductions in dopamine levels in the caudate‐putamen and the nucleus accumbens of transgenic G1H mice. In addition, numbers of tyrosine hydroxylase‐immunostained neurons were significantly reduced in both the substantia nigra (26%) and the ventral tegmental area (16%) compared to those in their nontransgenic littermates. Similar abnormalities were not observed in the brains of transgenic mice overexpressing wild‐type Cu/Zn‐SOD. These findings indicate that overexpression of the mutated Cu/Zn‐SOD protein caused a significant loss of midbrain dopaminergic neurons in addition to the loss of spinal motor neurons. The potential of the mutated enzyme to induce cell death extending beyond the motor neurons is consistent with the description of substantia nigra degeneration in some patients with familial amyotrophic lateral sclerosis. Furthermore, if mutated Cu/Zn‐SOD is conclusively shown to kill cells by oxidative stress, such an observation would be in keeping with the known sensitivity of dopaminergic neurons to free radical attack.

[1]  R. Sidman,et al.  Atlas of the Mouse Brain and Spinal Cord , 1971 .

[2]  L. Kurland,et al.  Familial amyotrophic lateral sclerosis. A subgroup characterized by posterior and spinocerebellar tract involvement and hyaline inclusions in the anterior horn cells. , 1967, Archives of neurology.

[3]  M. Pericak-Vance,et al.  Amyotrophic lateral sclerosis and structural defects in Cu,Zn superoxide dismutase. , 1993, Science.

[4]  D. Borchelt,et al.  Superoxide dismutase is an abundant component in cell bodies, dendrites, and axons of motor neurons and in a subset of other neurons. , 1995, Proceedings of the National Academy of Sciences of the United States of America.

[5]  C. Marsden,et al.  Sequence of the superoxide dismutase 1 (SOD 1) gene in familial Parkinson's disease. , 1995, Journal of neurology, neurosurgery, and psychiatry.

[6]  S. Varon,et al.  Ciliary neurotrophic factor prevents degeneration of adult rat substantia nigra dopaminergic neurons in vivo. , 1993, Proceedings of the National Academy of Sciences of the United States of America.

[7]  H. Hayashi,et al.  Amyotrophic lateral sclerosis patients living beyond respiratory failure , 1991, Journal of the Neurological Sciences.

[8]  O. Elroy-Stein,et al.  Cell damage by excess CuZnSOD and Down's syndrome. , 1994, Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie.

[9]  A. Björklund,et al.  Brain-derived neurotrophic factor enhances function rather than survival of intrastriatal dopamine cell-rich grafts , 1993, Brain Research.

[10]  R. Marttila,et al.  Oxygen toxicity protecting enzymes in Parkinson's disease Increase of superoxide dismutase-like activity in the substantia nigra and basal nucleus , 1988, Journal of the Neurological Sciences.

[11]  M. Lovett,et al.  Transgenic mice with increased Cu/Zn-superoxide dismutase activity: animal model of dosage effects in Down syndrome. , 1987, Proceedings of the National Academy of Sciences of the United States of America.

[12]  W. Engel,et al.  Amyotrophic lateral sclerosis: metabolism of central monoamines and treatment with L-dopa. , 1971, Transactions of the American Neurological Association.

[13]  R. Coggeshall,et al.  Methods for determining numbers of cells and synapses: A case for more uniform standards of review , 1996, The Journal of comparative neurology.

[14]  D. Reis,et al.  Genetic control of number of midbrain dopaminergic neurons in inbred strains of mice: relationship to size and neuronal density of the striatum. , 1980, Proceedings of the National Academy of Sciences of the United States of America.

[15]  J. Haines,et al.  Mutations in Cu/Zn superoxide dismutase gene are associated with familial amyotrophic lateral sclerosis , 1993, Nature.

[16]  G. Rosoklija,et al.  Brain superoxide dismutase, catalase, and glutathione peroxidase activities in amyotrophic lateral sclerosis , 1996, Annals of neurology.

[17]  D. Bredesen,et al.  Altered Reactivity of Superoxide Dismutase in Familial Amyotrophic Lateral Sclerosis , 1996, Science.

[18]  C. Epstein,et al.  3‐Nitropropionic Acid Neurotoxicity Is Attenuated in Copper/Zinc Superoxide Dismutase Transgenic Mice , 1995, Journal of neurochemistry.

[19]  C. Marsden,et al.  A Selective Increase in Particulate Superoxide Dismutase Activity in Parkinsonian Substantia Nigra , 1989, Journal of neurochemistry.

[20]  D. Togasaki,et al.  Dose-dependent lesions of the dopaminergic nigrostriatal pathway induced by instrastriatal injection of 6-hydroxydopamine , 1995, Neuroscience.

[21]  M. Gurney,et al.  Age-Dependent Penetrance of Disease in a Transgenic Mouse Model of Familial Amyotrophic Lateral Sclerosis , 1995, Molecular and Cellular Neuroscience.

[22]  C. Epstein,et al.  Transgenic mice with increased Cu/Zn-superoxide dismutase activity are resistant to N-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced neurotoxicity , 1992, The Journal of neuroscience : the official journal of the Society for Neuroscience.

[23]  D. Borchelt,et al.  Mutations associated with amyotrophic lateral sclerosis convert superoxide dismutase from an antiapoptotic gene to a proapoptotic gene: studies in yeast and neural cells. , 1995, Proceedings of the National Academy of Sciences of the United States of America.

[24]  M. Gurney,et al.  Benefit of vitamin E, riluzole, and gababapentin in a transgenic model of familial amyotrophic lateral sclerosis , 1996, Annals of neurology.

[25]  V. Dhawan,et al.  Nigrostriatal dopaminergic function in familial amyotrophic lateral sclerosis patients with and without copper/zinc superoxide dismutase mutations , 1996, Neurology.

[26]  C. Epstein,et al.  Increased Superoxide Dismutase Activity Improves Survival of Cultured Postnatal Midbrain Neurons , 1996, Journal of neurochemistry.

[27]  M. Beal,et al.  Motor neurons in Cu/Zn superoxide dismutase-deficient mice develop normally but exhibit enhanced cell death after axonal injury , 1996, Nature Genetics.

[28]  S. Fahn,et al.  The oxidant stress hypothesis in Parkinson's disease: Evidence supporting it , 1992, Annals of neurology.

[29]  M. Oda,et al.  Diminution of dopaminergic neurons in the substantia nigra of sporadic amyotrophic lateral sclerosis , 1993, Neuropathology and applied neurobiology.

[30]  M. Gurney,et al.  Motor neuron degeneration in mice that express a human Cu,Zn superoxide dismutase mutation. , 1994, Science.

[31]  L. Rowland Amyotrophic lateral sclerosis: human challenge for neuroscience. , 1995, Proceedings of the National Academy of Sciences of the United States of America.

[32]  T. Dawson,et al.  Role of neuronal nitric oxide in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-induced dopaminergic neurotoxicity. , 1996, Proceedings of the National Academy of Sciences of the United States of America.